|EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss|
JH Sampson, BD Choi, L Sanchez-Perez, CM Suryadevara, DJ Snyder, ...
Clinical Cancer Research 20 (4), 972-984, 2014
|EGFRvIII‐targeted vaccination therapy of malignant glioma|
BD Choi, GE Archer, DA Mitchell, AB Heimberger, RE McLendon, ...
Brain pathology 19 (4), 713-723, 2009
|Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma|
BD Choi, CT Kuan, M Cai, GE Archer, DA Mitchell, PC Gedeon, ...
Proceedings of the National Academy of Sciences 110 (1), 270-275, 2013
|EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma|
H Miao, BD Choi, CM Suryadevara, L Sanchez-Perez, S Yang, G De Leon, ...
PloS one 9 (4), e94281, 2014
|Bispecific antibodies engage T cells for antitumor immunotherapy|
BD Choi, M Cai, DD Bigner, AI Mehta, CT Kuan, JH Sampson
Expert opinion on biological therapy 11 (7), 843-853, 2011
|Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma|
BD Choi, CM Suryadevara, PC Gedeon, JE Herndon II, L Sanchez-Perez, ...
Journal of Clinical Neuroscience 21 (1), 189-190, 2014
|Myeloablative temozolomide enhances CD8+ T-cell responses to vaccine and is required for efficacy against brain tumors in mice|
LA Sanchez-Perez, BD Choi, GE Archer, X Cui, C Flores, LA Johnson, ...
PloS one 8 (3), e59082, 2013
|Factors influencing fellowship selection, career trajectory, and academic productivity among plastic surgeons|
MR DeLong, DB Hughes, VJ Tandon, BD Choi, MR Zenn
Plastic and reconstructive surgery 133 (3), 730-736, 2014
|Are BiTEs the “missing link” in cancer therapy?|
CM Suryadevara, PC Gedeon, L Sanchez-Perez, T Verla, ...
Oncoimmunology 4 (6), e1008339, 2015
|Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody|
BD Choi, PC Gedeon, JE Herndon, GE Archer, EA Reap, ...
Cancer immunology research 1 (3), 163-167, 2013
|Immunotherapy for malignant glioma|
CM Suryadevara, T Verla, L Sanchez-Perez, EA Reap, BD Choi, PE Fecci, ...
Surgical neurology international 6 (Suppl 1), S68, 2015
|Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody|
BD Choi, PC Gedeon, L Sanchez-Perez, DD Bigner, JH Sampson
Oncoimmunology 2 (12), e26757, 2013
|Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review|
TR Hodges, BD Choi, DD Bigner, H Yan, JH Sampson
Journal of neurosurgery 118 (6), 1176-1180, 2013
|A novel bispecific antibody recruits T cells to eradicate tumors in the “immunologically privileged” central nervous system|
BD Choi, I Pastan, DD Bigner, JH Sampson
Oncoimmunology 2 (4), e23639, 2013
|Convection enhanced delivery of macromolecules for brain tumors|
A I Mehta, B D Choi, D Ajay, R Raghavan, M Brady, A H Friedman, ...
Current drug discovery technologies 9 (4), 305-310, 2012
|Imaging of convection enhanced delivery of toxins in humans|
AI Mehta, BD Choi, R Raghavan, M Brady, AH Friedman, DD Bigner, ...
Toxins 3 (3), 201-206, 2011
|Enzyme redesign guided by cancer-derived IDH1 mutations|
ZJ Reitman, BD Choi, I Spasojevic, DD Bigner, JH Sampson, H Yan
Nature chemical biology 8 (11), 887, 2012
|Impact of PhD training on scholarship in a neurosurgical career|
BD Choi, MR DeLong, DM DeLong, AH Friedman, JH Sampson
Journal of neurosurgery 120 (3), 730-735, 2014
|Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic|
PC Gedeon, BD Choi, JH Sampson, DD Bigner
Drugs of the Future 38 (3), 147, 2013
|An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma|
PC Gedeon, BD Choi, TR Hodges, DA Mitchell, DD Bigner, JH Sampson
Expert review of clinical pharmacology 6 (4), 375-386, 2013